Quoin Pharmaceuticals (2EB0) Price & Analysis

0 Followers

2EB0 Stock Chart & Stats

€4.70

€0.04(1.20%)

At close: Jul 30 4:00 PM EDT

€4.70

€0.04(1.20%)

Day’s Range― - ―

52-Week Range€2.80 - €25.00

Previous CloseN/A

Volume0.00

Average Volume (3M)21.00

Market Cap

€12.07M

Enterprise Value-€1.08

Total Cash (Recent Filing)€10.80M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta-0.18

Next Earnings

Nov 05, 2026

EPS Estimate

-1.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-14.89

Shares Outstanding2,008,418

10 Day Avg. Volume4

30 Day Avg. Volume21

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)1.65

Price to Sales (P/S)0.00

P/FCF Ratio-1.60

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€23.63

Price Target Upside402.66% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-5.62

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Regulatory And Clinical ProgressQRX003 is advancing through meaningful regulatory and clinical milestones in severe pediatric dermatological diseases with no approved treatments. Additional designations and positive interim data could improve development and approval prospects, strengthening Quoin’s pipeline position over the next several quarters.

Extended Clinical Funding RunwayThe financing provides substantial additional time to conduct QRX003 development without an immediate funding requirement. A longer runway supports execution of planned trials and regulatory work, reducing near-term liquidity pressure while allowing the company to pursue important value-creating milestones.

Debt-free Balance SheetThe absence of reported debt limits fixed repayment obligations and interest-related pressure while Quoin remains focused on clinical development. This gives management greater flexibility to direct available resources toward trials and regulatory preparation, despite the company’s ongoing operating losses.

Bears Say

No Commercial Revenue And Widening LossesQuoin has not yet demonstrated commercial revenue generation, and its more recent losses are widening as development spending continues. Until a product is approved and launched, the business remains dependent on external capital and exposed to prolonged negative earnings.

Accelerating Cash BurnIncreasingly negative free cash flow indicates that Quoin is consuming cash faster as it advances its programs. Persistent operating outflows reduce financial resilience and make future financings important for sustaining clinical work, even though the recent placement extends the stated runway.

Shrinking Equity And AssetsThe sharp contraction in equity and total assets reflects accumulated losses and ongoing cash consumption, weakening the company’s financial base. Continued deterioration can increase reliance on equity issuance and may erode existing shareholders’ ownership and long-term value.

Quoin Pharmaceuticals News

Quoin Pharmaceuticals granted Rare Pediatric Disease Designation for QRX003

Quoin Pharmaceuticals (QNRX) announced that the FDA has granted Rare Pediatric Disease Designation for the company’s lead asset,...

10d ago

QNRX

Quoin Pharmaceuticals announces $50M private placement

Quoin Pharmaceuticals (QNRX) announced that it has entered into a securities purchase agreement with new and existing healthcare-focused...

21d ago

QNRX

Quoin Pharmaceuticals reports ‘positive’ data from Phase 2/3 study of QRX003

Quoin Pharmaceuticals (QNRX) announced positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion...

21d ago

QNRX

Quoin Pharmaceuticals Gains FDA Rare Pediatric Designation

Quoin Pharmaceuticals ( ($QNRX) ) has issued an update. On September 8, 2026, Quoin Pharmaceuticals reported that the...

8d ago

QNRX

Quoin Reports Positive Interim QRX003 Netherton Data

Quoin Pharmaceuticals ( ($QNRX) ) just unveiled an update. On August 27, 2026, Quoin Pharmaceuticals entered into a...

21d ago

QNRX

Quoin Pharmaceuticals Shareholders Approve Governance and Compensation Changes

Quoin Pharmaceuticals ( ($QNRX) ) has provided an announcement. At its 2026 Annual General Meeting of Shareholders held...

29d ago

QNRX

Quoin Pharmaceuticals reports Q2 EPS ($1.90), consensus ($1.77)

“The second quarter was a highly productive period across both of our delivery technology platforms,” said Michael Myers,...

1M ago

QNRX

QNRX Upcoming Earnings Report: What to Expect?

Quoin Pharmaceuticals Ltd (QNRX) is scheduled to report 2nd quarter earnings on 08/14/2026, before the market opens. Regarding...

1M ago

QNRX

Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application

Quoin Pharmaceuticals (QNRX) announced that the FDA has cleared the company’s investigational new drug, or IND, application for...

2M ago

QNRX

Quoin Pharmaceuticals receives notice of allowance for QRX003 patent

Quoin Pharmaceuticals (QNRX) announced that the United States Patent and Trademark Office, or USPTO, has issued a notice...

3M ago

QNRX

Naz Rahman Maintains Buy on Quoin as QYLEKI Progress Offsets Financing Risks, While Cutting 12-Month Price Target from $40 to $16

Quoin Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from...

3M ago

QNRX

Quoin Advances QYLEKI Toward First Netherton Therapy

Quoin Pharmaceuticals ( ($QNRX) ) has issued an update. On June 23, 2026, Quoin Pharmaceuticals said the U.S....

3M ago

QNRX

Quoin Pharmaceuticals announces conditional FDA approval for Qyleki brand name

Quoin Pharmaceuticals (QNRX) announced that the FDA has conditionally approved Qyleki as the proposed brand name for QRX003,...

3M ago

QNRX

Quoin Pharmaceuticals completes establishment of subsidiary in Japan

Quoin Pharmaceuticals (QNRX) announced that it has completed the establishment of a wholly-owned subsidiary in Japan as part...

3M ago

QNRX

2EB0 FAQ

What was Quoin Pharmaceuticals’s price range in the past 12 months?

Quoin Pharmaceuticals lowest stock price was €2.80 and its highest was €25.00 in the past 12 months.

What is Quoin Pharmaceuticals’s market cap?

Quoin Pharmaceuticals’s market cap is €12.07M.

When is Quoin Pharmaceuticals’s upcoming earnings report date?

Quoin Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 48 days.

How were Quoin Pharmaceuticals’s earnings last quarter?

Quoin Pharmaceuticals released its earnings results on Aug 14, 2026. The company reported -€1.641 earnings per share for the quarter, missing the consensus estimate of -€1.391 by -€0.25.

Is Quoin Pharmaceuticals overvalued?

According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Quoin Pharmaceuticals pay dividends?

Quoin Pharmaceuticals does not currently pay dividends.

What is Quoin Pharmaceuticals’s EPS estimate?

Quoin Pharmaceuticals’s EPS estimate is -1.41.

How many shares outstanding does Quoin Pharmaceuticals have?

Quoin Pharmaceuticals has 2,008,418 shares outstanding.

What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?

Quoin Pharmaceuticals reported an EPS of -€1.641 in its last earnings report, missing expectations of -€1.391. Following the earnings report the stock price went up 6.092%.

Which hedge fund is a major shareholder of Quoin Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:2EB0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.

Quoin Pharmaceuticals (2EB0) Earnings & Revenues

Historic Earnings Reports

2EB0 Stock 12 Month Forecast

Average Price Target

€23.63

▲(402.66% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","31":"€31","9.25":"€9.25","16.5":"€16.5","23.75":"€23.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.06841845,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.07</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.625185925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€23.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.1819534,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.18</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.25,16.5,23.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,6.651416803846154,8.602833607692308,10.554250411538462,12.505667215384616,14.45708401923077,16.408500823076924,18.359917626923078,20.311334430769232,22.262751234615383,24.214168038461537,26.16558484230769,28.117001646153845,{"y":30.06841845,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,6.155783532692308,7.611567065384616,9.067350598076924,10.523134130769233,11.97891766346154,13.434701196153846,14.890484728846154,16.346268261538462,17.80205179423077,19.25783532692308,20.713618859615387,22.169402392307692,{"y":23.625185925,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,5.660150261538462,6.620300523076923,7.580450784615385,8.540601046153848,9.500751307692308,10.46090156923077,11.421051830769233,12.381202092307694,13.341352353846155,14.301502615384617,15.26165287692308,16.221803138461542,{"y":17.1819534,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.4,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.08,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.88,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.58,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >